TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03939793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPaCT Community Health Worker
Description: Once a CHW receives notification of a struggling patient, the CHW will visit the patient at their home within 1-2 days to initiate the IMPaCT intervention.~1. Elements of the standard IMPaCT intervention: During the first home visit, the CHW will use an in-depth semi-structured interview guide to get to know patients holistically and assess for unmet socioeconomic needs. This allows patients to express goals in line with their own needs and preferences. These individualized goals will become the basis for tailored action plans. The CHW will then provide hands-on, tailored support for the remainder of the 24-week study period to help patients achieve their goals.~2. Additional elements to help patients cope with failure: In this study, we will test a refined version of IMPaCT that incorporates two behavioral techniques for coping with failure: positive affect induction and attribution retraining.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital health monitoring with financial incentives
Description: Participants are encouraged to use their glucometer to check their blood glucose via bidirectional texting and lottery-based financial incentives, which both serve to reinforce self-monitoring behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital health monitoring with financial incentives
Description: Participants are encouraged to use their glucometer to check their blood glucose via bidirectional texting and lottery-based financial incentives, which both serve to reinforce self-monitoring behavior.
Study: NCT04696302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus of attention
Description: Individuals were asked to laterally weight shift while seated with either internal focus or external focus instructions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus of attention
Description: Individuals were asked to laterally weight shift while seated with either internal focus or external focus instructions.
Study: NCT01125397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEARN group
Description: Participants will complete a 12-week behavioral weight management intervention (the LEARN program) prior to bariatric surgery, which is the current standard clinical practice at Mayo Clinic Rochester. This involves weekly group meetings, weigh-ins, and goal setting.
Study: NCT00571324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39)
Description: A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exendin-(9-39)
Description: A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.
Study: NCT01358435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30% Regular Insulin Human Neutral and 70%Isophane Insulin
Description: Total Dose per subject is 0.4 IU/Kg given subcutaneously.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novolin 70/30
Description: Total Dose per subject is 0.4IU/Kg given Subcutaneously.
Study: NCT01268553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Transition to inhaled treprostinil
Study: NCT02487407

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ODM-109
Description: Placebo capsule for oral administration.
Study: NCT03939793

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study: NCT01296776

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: wellness control group.
Description: Light physical exercise and relaxation program once a week in blocks of 10 weeks with breaks of 10 weeks between the blocks. The low-intensity, low-volume program was designed to avoid impact on our endpoints.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: whole-body electromyostimulation
Description: 3 sessions of 18 min/14 (1,5 x week)days over 12 months. 10 low-intensity/low amplitude exercises with electromyostimulation equipment with 85 Hz with periods of 6 sec of current and 4 sec of rest.
Study: NCT04344899

Intervention type: OTHER
Intervention: Observational
Description: Enhanced Recovery After Surgery protocol at five tertiary-care pediatric hospitals in pediatric patients undergoing abdominal or retroperitoneal surgical resections for cancer.

Intervention type: OTHER
Intervention: Observational
Description: Enhanced Recovery After Surgery protocol at five tertiary-care pediatric hospitals in pediatric patients undergoing abdominal or retroperitoneal surgical resections for cancer.
Study: NCT03287141

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Shuttle walk test
Description: A shuttle walk test was performed without any previous intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (Bi-pap)
Description: After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (CPAP)
Description: After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
Study: NCT00583128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: oral, sachet, 2 grams three times daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celphere® CP-305
Description: oral, placebo, sachet, 2 grams three times daily for 8 weeks
Study: NCT01278186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Description: Coronary angioplasty using the paclitaxel-coated balloon catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent implantation
Description: Coronary angioplasty using the paclitaxel-eluting stent
Study: NCT00830271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicryl plus and Monocryl plus
Description: closure of skin and subcutaneous tissues

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wound closure with Vicryl and Monocryl
Description: wound closure skin and subcutaneous tissues
Study: NCT03533608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group PE
Description: Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
Study: NCT00865306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents.
Description: This is a cognitive-behavioral intervention modeled loosely after Kendall's Coping Cat, which includes 7 parent-only sessions and 8-13 child-only sessions. It focuses on helping parents learn strategies for coaching their child in coping with anxiety, and on teaching the child coping skills and carrying out exposure exercises in session and in parent-child homework assignments.
Study: NCT03941756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Given IV
Study: NCT03942757

Intervention type: OTHER
Intervention: bilirubin serum level determination
Description: bilirubin serum level before and after phototherapy treatment will be measured

Intervention type: OTHER
Intervention: bilirubin serum level determination
Description: bilirubin serum level before and after phototherapy treatment will be measured

Intervention type: OTHER
Intervention: Phototherapy
Description: Preterm infant \< 35 weeks of gestation with a jaundice requiring phototherapy according to NICE guidelines can be included for the duration of the phototherapy treatment.
Study: NCT03941756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphangiography
Description: Undergo lymphangiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphovenous Bypass
Description: Undergo LVB
Study: NCT01975701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: Capsule for oral use.
Study: NCT03942757

Intervention type: OTHER
Intervention: Phototherapy
Description: Preterm infant \< 35 weeks of gestation with a jaundice requiring phototherapy according to NICE guidelines can be included for the duration of the phototherapy treatment.
Study: NCT00435331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin dihydrochloride (6R-BH4)
Description: 2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days
Study: NCT03439241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast ostomy device
Description: the test product is a newly developed Coloplast ostomy device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast ostomy device
Description: the test product is a newly developed Coloplast ostomy device
Study: NCT02588898

Intervention type: DEVICE
Intervention: Blood collection and electrophysiological tests
Description: Blood collected using a conventional method. Electrophysiology was tested after nerve Stimulation. Medical history and symptoms were collected after a standardized interview.

Intervention type: DEVICE
Intervention: Blood collection and electrophysiological tests
Description: Blood collected using a conventional method. Electrophysiology was tested after nerve Stimulation. Medical history and symptoms were collected after a standardized interview.
Study: NCT00776841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: 1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
Study: NCT01655498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vaginal bowel control system (LivSure)
Study: NCT04109209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Intervention Group
Description: The intervention will consist of six one-on-one sessions (45 minutes each). Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~•Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks
Study: NCT02167230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jailed-balloon technique
Description: A monorail balloon is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to nominal pressure, the balloon in SB is inflated to 3 atm generally but to higher pressure to perform angioplasty if the blood flow in SB is compromised. The balloon in SB is then removed while the wire in SB is left in place. The MB stent balloon is inflated again for stent apposition. The SB wire is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the stent balloon is inflated again.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Jailed-wire technique
Description: A percutaneous transluminal coronary angioplasty(PTCA) wire is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to some pressure to achieve full apposition, the wire in SB is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the MB stent is deployed.
Study: NCT01928888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talcid (Hydrotalcite, BAY4516H)
Description: 2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
Study: NCT00776841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: 1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: 1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: 1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: 1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: 1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aramchol
Description: 1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Oral Aramchol at dose 30 mg to 900 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Oral Aramchol at dose 30 mg to 900 mg
Study: NCT01928888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talcid (Hydrotalcite, BAY4516H)
Description: 2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talcid (Hydrotalcite, BAY4516H)
Description: 2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talcid (Hydrotalcite, BAY4516H)
Description: 2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
Study: NCT00776841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Oral Aramchol at dose 30 mg to 900 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Oral Aramchol at dose 30 mg to 900 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aramchol
Description: Oral Aramchol at dose 30 mg to 900 mg
Study: NCT01928888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talcid (Hydrotalcite, BAY4516H)
Description: 2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talcid (Hydrotalcite, BAY4516H)
Description: 2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
Study: NCT00776841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
Study: NCT04223141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIA
Description: As indicated by arm description
Study: NCT02246556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dichoptic therapy
Description: Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching therapy
Description: Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dioptic (non-dichoptic) therapy
Description: Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
Study: NCT01686256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m EC20
Description: Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
Study: NCT00874172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid optimized analgesic strategy
Description: Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: current analgesic strategy
Description: paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration
Study: NCT04232410

Intervention type: DIAGNOSTIC_TEST
Intervention: Drug induced sleep endoscopy
Description: DISE is performed in a semi-dark, silent operating theatre, starting with the patient in supine position. To first induce sleep, an IV bolus of midazolam (1.5 mg) is administered. Then, a flexible fiberoptic nasopharyngoscope (Olympus END-GP, 3.7 mm diameter, Olympus Europe GmbH, Hamburg, Germany) is inserted through one of the nostrils. Either at the start of the examination or while holding the scope at the level of the palate, propofol (2.0-3.0 µg/ml) will be administered via a target-controlled infusion (TCI) pump. Sleep occurrence is confirmed using the additional EEG measurement.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of critical closing pressure of the uppper airway
Description: After sleep onset, the CPAP pressure well be increased until no flow limitations are observed. This pressure is called the holding pressure and is used as a base for all the following measurements for that individual OSA patient. After observing sleep stage 2 or 3, the holding pressure is reduced abruptly by 1 cmH2O during expiration for 5 breaths. Then the pressure is set back to the holding pressure for the duration of 1 minute. This procedure is repeated until obstructive sleep apnea is noted.
Study: NCT04160871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Connections
Description: Intervention includes 12 sessions that follow a group format of 2 hours with a weekly frequency. FC program (Hoffman and Fruzzetti, 2005) is divided into six modules: 1: Updated information and research on BPD; 2: Psychoeducation on the development of BPD, available treatments and comorbidity; 3: Individual skills: self-control of emotions, mindfulness, reality acceptance skills, validation skills, etc. and skills of relationship to promote emotional well-being problem management (family skills); 4: Family skills to improve the quality of relationships in family interactions; 5: Communication skills and effective self-expression; and 6: Problem management. All modules include Practice exercises and homework. In addition, throughout the program, in order to increase social support, the FC program provides a forum where participants can stay in touch, share common problems and solutions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: The intervention lasts for 3 months and includes 12 sessions that follow a group format of 2 hours and with a weekly frequency. It includes the following components: Psychoeducation about personality disorders and, specifically, BPD and how these disorders evolve. Problems associated with BPD (eg, alcohol and / or drug use, eating disorders, etc.). The importance of modeling in family members: change of attitude towards difficult situations to reduce the escalation of tension and re-establish a healthy relationship between the patient and family. The handling of problems. Crisis management: Development of safe plans for when the patient is in emotional escalation.
Study: NCT00988429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 800 mg QD Eslicarbazepine acetate
Description: Oral, 800 mg QD, 2-week titration period and 12-week maintenance period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1200 mg QD Eslicarbazepine acetate
Description: Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet given QD
Study: NCT02112799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVR 3-778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVR 3-778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for NVR 3-778
Description: Sugar pill manufactured to mimic the NVR 3-778 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Study: NCT05734235

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Two Vitamin C tablets daily for 8 days.